Instead, the cap would shift costs to others through higher insurance premiums and copays, the group said in a March 31 news release.
The group said it supports real solutions to drug affordability and blamed the pharmaceutical industry for high insulin prices.
“Rather than holding Big Pharma accountable, this legislation continues to empower Big Pharma to raise insulin prices with impunity, leaving patients, businesses, and hardworking taxpayers paying even more for healthcare,” the group said.
